Jett Foundation Launches $10.7M Capital Campaign for Jett's Place, a Sanctuary for Duchenne Community

Jett Foundation announced a capital campaign to build Jett's Place, a wellness and retreat center for families affected by Duchenne muscular dystrophy, with initial $1 million gifts from the Emilson Family and ITF Therapeutics.

Miami Metrowire Staff
Healthcare
Jett Foundation Launches $10.7M Capital Campaign for Jett's Place, a Sanctuary for Duchenne Community

Jett Foundation announced its most ambitious milestone to date: the launch of a capital campaign to fund the building of Jett's Place, a premier wellness and retreat center serving as a dedicated sanctuary for individuals and families affected by Duchenne muscular dystrophy (DMD). The fundraising campaign was anchored in its initial phase by two transformative $1 million donations from the Emilson Family and ITF Therapeutics.

Located on a 10-acre campus in Norwell, Massachusetts, Jett's Place will serve as Jett Foundation's national headquarters and provide barrier-free accessibility, specialized wellness care, adaptive nature and recreation, and educational programs designed with input from Duchenne families. The campaign sets a $10.7 million goal and has already raised over $5 million during its quiet phase, as Jett Foundation invites broader community support to bring the project to life.

Duchenne is a progressive neuromuscular disorder diagnosed during childhood that causes loss of motor, pulmonary, and cardiac function, and premature death. It affects every 1 in 5,000 live male births and some females. There is no cure. Children with Duchenne are born seemingly healthy and decline over time, usually losing the ability to walk around age 12 and succumbing to the disease in their early to mid-twenties.

Since 2001, Jett Foundation, headquartered in Norwell, Mass., has worked to empower people and families impacted by Duchenne through transformative programming, educational opportunities, and ongoing support for every stage of a Duchenne journey. More information about the foundation can be found at www.jettfoundation.org.

ITF Therapeutics, established in January 2024 as the U.S. affiliate of Italfarmaco Group, develops and commercializes treatments for rare diseases. The company combines end-to-end commercial execution with close listening to learn directly from advocates, researchers, clinicians, and families. For more information, visit www.itftherapeutics.com.

The announcement of Jett's Place marks a significant step forward for the Duchenne community, providing a dedicated space for wellness, education, and support. With over $5 million already raised, the capital campaign aims to reach its $10.7 million goal to create a barrier-free sanctuary that addresses the unique needs of individuals and families affected by DMD.

Blockchain Registration

QR Code for Blockchain Registration